尿标记物和影像学在间质性膀胱炎/膀胱疼痛综合征诊断中的潜在价值

马凯群; 张嘉鹏; 郑振明; 姚友生

doi:10.13201/j.issn.1001-1420.2019.10.018

尿标记物和影像学在间质性膀胱炎/膀胱疼痛综合征诊断中的潜在价值

- 中山大学孙逸仙纪念医院泌尿外科(广州, 510000)

详细信息

通讯作者: 姚友生,E-mail:yys430@126.com

中图分类号: R694

收稿日期: 2019-04-04

Potential value of urine markers and imaging in the diagnosis of interstitial cystitis/bladder pain syndrome

- Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510000, China

More Information

Corresponding author: YAO Yousheng, E-mail: yys430@126.com

Received Date: 04 April 2019

摘要

摘要: 间质性膀胱炎/膀胱疼痛综合征（IC/BPS）是一种病因尚未完全明确的疾病，目前提出的病因包括感染、自身免疫/炎症、肥大细胞、膀胱氨基葡聚糖和上皮渗透性、神经支配、尿液毒性物质等。由于病因尚未明确，IC/BPS的诊断和治疗也面临着极大的困难。目前主要的诊断手段还是临床表现和膀胱镜检伴或不伴膀胱水扩张。但二者的特异性和敏感性有限，不可避免导致IC/BPS的漏诊和误诊。在这种背景下，发现IC/BPS特异性的尿标记物和影像学表现必然可以极大地帮助IC/BPS的诊断治疗。本文主要对尿标记物和影像学的相关进展作一综述。
- 间质性膀胱炎/膀胱疼痛综合征 /
- 诊断 /
- 尿标记物 /
- 影像学
Abstract: Interstitial cystitis/bladder pain syndrome(IC/BPS) is a disease without specific pathogeny. There are several pathogenies including infection, autoimmunity, mast cells, mucosal epithelial permeability, neuropathic pain, toxic ingredient in urine and so on. It's diffficult to diagnose and treat IC/BPS because of its unclear pathogeny. The main diagnostic methods of IC/BPS are symptoms and cystoscope with hydrodistension or not. However, the sensitivity and specificity of these methods are inadequate. In this case, missed diagnosis and misdiagnosis of IC/BPS are inevitable. Apparently, discovering specific urine marker and imaging characteristic of IC/BPS is helpful in the diagnosis and treatment of IC/BPS. This article is aimed at reviewing the progress of urine markers and imaging in IC/BPS.
- interstitial cystitis/bladder pain syndrome /
- diagnosis /
- urine markers /
- imaging

HTML全文

参考文献(42)

[1]	Hanno P M, Burks D A, Clemens J Q, et al.AUAGuideline for the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome[J].J Urol, 2011, 185(6):2162-2170.
[2]	Cox A, Golda N, Nadeau G, et al.CUA guideline:Diagnosis and treatment of interstitial cystitis/bladder pain syndrome[J].Can Urol Assoc J, 2016, 10(5/6):E136-E155.
[3]	Wyndaele J J J, Riedl C, Taneja R, et al.GAG replenishment therapy for bladder pain syndrome/interstitial cystitis[J].Neurourol Urodyn, 2019, 38(2):535-544.
[4]	van Ophoven A, Vonde K, Koch W, et al.Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome:results of a systematic review of randomized controlled trials[J].Curr Med Res Opin, 2019, 8:1-9.
[5]	Sahiner I F, Soylu H, Ates E, et al.Impact of intravesical hyaluronic acid treatment on bladder inflammation in interstitial cystitis rat model[J].Int Braz J Urol, 2018, 44(5):1014-1022.
[6]	GülpınarÖ, Esen B, Kayı爧A, et al.Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis[J].Neurourol Urodyn, 2018, 37(1):257-262.
[7]	Sun Y, Chen M, Lowentritt B H, et al.EGF and HB-EGF modulate inward potassium current in human bladder urothelial cells from normal and interstitial cystitis patients[J].Am J Physiol Cell Physiol, 2007, 292(1):C106-C114.
[8]	Chavda B, Ling J, Majernick T, et al.Antiproliferative factor(APF)binds specifically to sites within the cytoskeleton-associated protein 4(CKAP4)extracellular domain[J].BMC Biochem, 2017, 18(1):13-13.
[9]	Chung S D, Huang C C, Lin H C, et al.Bladder pain syndrome/interstitial cystitis is associated with asthma:A case-control study[J].Neurourol Urodyn, 2018, 37(5):1773-1778.
[10]	Keller J J, Liu S P, Lin H C.A case-control study on the association between rheumatoid arthritis and bladder pain syndrome/interstitial cystitis[J].Neurourol Urodyn, 2013, 32(7):980-985.
[11]	Crescenze I M, Tucky B, Li J, et al.Efficacy, Side Effects, and Monitoring of Oral Cyclosporine in Interstitial Cystitis-Bladder Pain Syndrome[J].Urology, 2017, 107:49-54.
[12]	Kaneko G, Nishimoto K, Ito Y, et al.The combination therapy of prednisolone and tacrolimus for severe painful bladder syndrome/interstitial cystitis[J].Can Urol Assoc J, 2012, 6(2):E46-E49.
[13]	Erickson D R, Xie S X, Bhavanandan V P, et al.A comparison of multiple urine markers for interstitial cystitis[J].J Urol, 2002, 167(6):2461-2469.
[14]	Abernethy M G, Rosenfeld A, White J R, et al.Urinary Microbiome and Cytokine Levels in Women With Interstitial Cystitis[J].Obstet Gynecol, 2017, 129(3):500-506.
[15]	Lv Y S, Yao Y S, Lin M E, et al.Interleukin-6levels in female rats with protamine sulfate-induced chronic cystitis treated with hyaluronic acid.[J].Int J Urol, 2013, 20(10):1017-1022.
[16]	荣禄, 姚友生, 林明恩, 等.间质性膀胱炎中膀胱上皮共表达干细胞因子和白细胞介素-6及其意义[J].中华实验外科杂志, 2013, 30(6):1161-1163.
[17]	Logadottir Y, Delbro D, Fall M, et al.Cytokine expression in patients with bladder pain syndrome/interstitial cystitis ESSIC type 3C[J].J Urol, 2014, 192(5):1564-1568.
[18]	Daha L K, Lazar D, Simak R, et al.Is there a relation between urinary interleukin-6levels and symptoms before and after intra-vesical glycosaminoglycan substitution therapy in patients with bladder pain syndrome/interstitial cystitis?[J].Int Urogynecol J Pelvic Floor Dysfunct, 2007, 18(12):1449-1452.
[19]	Sairanen J, Hotakainen K, Tammela T L, et al.Urinary epidermal growth factor and interleukin-6levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium[J].Urology, 2008, 71(4):630-633.
[20]	Majima T, Mori K, Kadekawa K, et al.The effect of herpes simplex virus vector-mediated gene therapy of protein phosphatase 1α on bladder overactivity and nociception[J].Neurourol Urodyn, 2019, 38(2):582-590.
[21]	Sahiner I F, Soylu H, Ates E, et al.Impact of intravesical hyaluronic acid treatment on bladder inflammation in interstitial cystitis rat model[J].Int Braz J Urol, 2018, 44(5):1014-1022.
[22]	Tseng-Rogenski S, Liebert M.Interleukin-8is essential for normal urothelial cell survival[J].Am J Physiol Renal Physiol, 2009, 297(3):F816-F821.
[23]	Jiang Y H, Peng C H, Liu H T, et al.Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome[J].PLoS One, 2013, 8(10):e76779.
[24]	Jang T Y, Kim Y H.Interleukin-33and Mast Cells Bridge Innate and Adaptive Immunity:From the Allergologist's Perspective[J].Int Neurourol J, 2015, 19(3):142-150.
[25]	Martin Jensen M, Jia W, Schults A J, et al.IL-33 mast cell axis is central in LL-37induced bladder inflammation and pain in a murine interstitial cystitis model[J].Cytokine, 2018, 110:420-427.
[26]	Hosseini A, Ehrén I, Wiklund N P.Nitric oxide as an objective marker for evaluation of treatment response in patients with classic interstitial cystitis[J].J Urol, 2004, 172(6Pt 1):2261-2265.
[27]	Gamper M, Moser R, Viereck V.Have we been led astray by the NGF biomarker data?[J].Neurourol Urodyn, 2017, 36(1):203-204.
[28]	Furuta A, Yamamoto T, Suzuki Y, et al.Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder[J].Int Urogynecol J, 2018, 29(7):961-966.
[29]	Niimi A, Igawa Y, Aizawa N, et al.Diagnostic value of urinary CXCL10as a biomarker for predicting Hunner type interstitial cystitis.[J].Neurourol Urodyn, 2018, 37(3):1113-1119.
[30]	Vera P L, Preston D M, Moldwin R M, et al.Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions:A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients.[J].Urology, 2018, 116:55-62.
[31]	徐曦, 张嘉鹏, 王健, 等.NALP3炎症小体在间质性膀胱炎/膀胱疼痛综合征中的表达及作用[J].中华泌尿外科杂志, 2018, 39(8):619-625.
[32]	Shahid M, Lee M Y, Yeon A, et al.Menthol, a unique urinary volatile compound, is associated with chronic inflammation in interstitial cystitis[J].Sci Rep, 2018, 8(1):10859.
[33]	Oelke M, Khullar V, Wijkstra H.Review on ultrasound measurement of bladder or detrusor wall thickness in women:techniques, diagnostic utility, and use in clinical trials.[J].World J Urol, 2013, 31(5):1093-1104.
[34]	Kaneko G, Nishimoto K, Ito Y, et al.The combination therapy of prednisolone and tacrolimus for severe painful bladder syndrome/interstitial cystitis[J].Can Urol Assoc J, 2012, 6(2):E46-E49.
[35]	Li S, Shi S, Li A, et al.Diffusion-Weighted Magnetic Resonance Imaging in Assessment of Primary Liver Cancer after HIFU Treatment[J].J Coll Physicians Surg Pak, 2019, 29(4):305-308.
[36]	Maeda D, Akiyama Y, Morikawa T, et al.Hunner-type(classic)interstitial cystitis:a distinct inflammatory disorder characterized by pancystitis, with frequent expansion of clonal B-cells and epithelial denudation[J].PLoSOne, 2015, 10(11):e0143316.
[37]	Magnotta V A, Friedman L, FIRST BIRN.Measurement of Signal-to-Noise and Contrast-to-Noise in the fBIRNMulticenter Imaging Study[J].J Digit Imaging, 2006, 19(2):140-147.
[38]	Tyagi P, Janicki J, Moon C H, et al.Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1mapping:applications in interstitial cystitis and beyond[J].IntUrolNephrol, 2018, 50(3):401-409.
[39]	Kairys A E, Schmidt-Wilcke T, Puiu T, et al.Increased brain gray matter in the primary somatosensory cortex is associated with increased pain and mood disturbance in patients with interstitial cystitis/painful bladder syndrome[J].J Urol, 2015, 193(1):131-137.
[40]	Kilpatrick L A, Kutch J J, Tillisch K, et al.Alterations in resting state oscillations and connectivity in sensory and motor networks in women with interstitial cystitis/painful bladder syndrome[J].J Urol, 2014, 192(3):947-955.
[41]	Maeda D, Akiyama Y, Morikawa T, et al.Hunner-Type(Classic)Interstitial Cystitis:A Distinct Inflammatory Disorder Characterized by Pancystitis, with Frequent Expansion of Clonal B-Cells and Epithelial Denudation.[J].PLoS One, 2015, 10:e0143316.
[42]	Denson M A, Griebling T L, Cohen M B, et al.Comparison of cystoscopic and histological findings in patients with suspected interstitial cystitis[J].J Urol, 2000, 164(6):1908-1911.